IPCALAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | IPCALAB | Market Cap | 39,274 Cr. | Current Price | 1,550 ₹ | High / Low | 1,624 ₹ |
| Stock P/E | 39.1 | Book Value | 292 ₹ | Dividend Yield | 0.26 % | ROCE | 17.6 % |
| ROE | 12.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,487 ₹ | DMA 200 | 1,433 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | 0.54 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 57.7 | MACD | 22.3 | Volume | 2,72,043 | Avg Vol 1Wk | 4,44,268 |
| Low price | 1,168 ₹ | High price | 1,624 ₹ | PEG Ratio | -53.6 | Debt to equity | 0.11 |
| 52w Index | 83.8 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 27.6 |
📉 Chart & Trend: IPCALAB is trading above both its 50 DMA (₹1,487) and 200 DMA (₹1,433), with the current price at ₹1,550. This indicates short-term strength and medium-term bullish bias.
📊 RSI: At 57.7, RSI is neutral-to-positive, suggesting healthy momentum without being overbought.
📈 MACD: Positive at 22.3, confirming bullish momentum and potential continuation of the uptrend.
📉 Bollinger Bands: Price is mid-to-upper range, reflecting strength but with room for consolidation.
📊 Volume: Current volume (2.72 Lakh) is lower than average weekly volume (4.44 Lakh), showing reduced participation but still supportive of stability.
📍 Support & Resistance:
- Strong support: ₹1,487 (50 DMA)
- Immediate resistance: ₹1,600–₹1,624 (recent high)
- Major resistance: ₹1,650+
Optimal entry zone: ₹1,500–₹1,540 (near support).
Exit zone: ₹1,600–₹1,625 (resistance cluster).
🔎 Trend Status: The stock is trending upward with bullish bias. Sustained close above ₹1,600 could trigger further upside momentum.
Positive
- ROCE (17.6%) and ROE (12.6%) indicate solid capital efficiency.
- Low debt-to-equity (0.11) ensures financial stability.
- EPS at ₹31.7 supports earnings visibility.
- Strong 52-week index performance at 83.8% shows robust long-term momentum.
Limitation
- P/E of 39.1 compared to industry PE of 27.6 indicates overvaluation.
- PEG ratio of -53.6 reflects poor earnings growth visibility relative to valuation.
- Volume participation is lower than average, limiting breakout strength.
Company Negative News
- PAT declined slightly to ₹303 Cr from ₹305 Cr, showing earnings stagnation.
- High valuation multiples may limit upside in near term.
Company Positive News
- FII holding increased by 0.20% and DII holding by 0.54%, showing institutional confidence.
- Quarterly profit variation of 13.4% indicates growth momentum.
Industry
- Industry PE at 27.6 vs IPCALAB’s PE of 39.1 shows relative premium valuation.
- Pharma sector outlook remains positive with strong demand drivers and defensive characteristics.
Conclusion
⚖️ IPCALAB is trending upward with bullish bias. Short-term traders may consider entry around ₹1,500–₹1,540 with exits near ₹1,600–₹1,625. Long-term investors can accumulate gradually given strong fundamentals, but caution is advised due to high valuation.
Would you like me to extend this into a pharma basket overlay (Sun Pharma, Divi’s Lab, Cipla) so you can benchmark IPCALAB’s setup against sector leaders for confirmation signals?